ArticleeLife2021
Start codon disruption with CRISPR/Cas9 prevents murine Fuchs' endothelial corneal dystrophy.
Open access · goldAbstract read
In one paragraph
Article in eLife, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Type VIII collagen: advances in matrix biology and translational promise.Frontiers in bioengineering and biotechnology · 2025Pooled it
- Association between subjective symptoms and severity in patients with Fuchs endothelial corneal dystrophy.Japanese journal of ophthalmology · 2026Observational
- RNA delivery to the corneal endothelium using charge-altering releasable transporters.Science advances · 2026Article
- Targeting LRPPRC to improve corneal wound healing via augmenting autophagy and suppressing TGF-β/Smad signaling post-alkali burn.Journal of translational medicine · 2026Article
- Contemporary Endothelial Genome Editing Technologies: Towards Precision Genetic Medicine for Vascular Diseases.International journal of molecular sciences · 2026Review
- Targeted AAV6 gene therapy restores corneal endothelial function in three hereditary corneal dystrophies.Cell reports. Medicine · 2026Article
- Anatomically Guided Non-Viral CRISPR/Cas9 Delivery in the Eye: Overcoming Barriers for Precision Gene Therapy.Pharmaceutics · 2026Review
- Congenital Hereditary Endothelial Dystrophy: A Review of the Molecular Pathogenesis, Genetic Basis, and Emerging Treatments.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Advancements in CRISPR-based therapies for ocular pathologies: from disease mechanisms to intervention strategies.Theranostics · 2026Review
- Correlation between visual function and corneal backscatter by Scheimpflug imaging or anterior segment optical coherence tomography in Fuchs endothelial corneal dystrophy.Japanese journal of ophthalmology · 2025Article
- Emerging Innovations in the Treatment of Fuchs Endothelial Corneal Dystrophy: A Narrative Review.Medical sciences (Basel, Switzerland) · 2025Review
- Review
- Developing stem cells for corneal disease: recent developments and future perspectives.Regenerative medicine · 2025Review
- Iron-Sulfur Clusters and Iron Responsive Element Binding Proteins Mediate Iron Accumulation in Corneal Endothelial Cells in Fuchs Dystrophy.Investigative ophthalmology & visual science · 2025Article
- Advancements in bioengineering for descemet membrane endothelial keratoplasty (DMEK).NPJ Regenerative medicine · 2025Review
- Review
- Genetic engineering and the eye.Eye (London, England) · 2025Review
- A tool for CRISPR-Cas9 sgRNA evaluation based on computational models of gene expression.Genome medicine · 2024Article
- Associations Between Visual Functions and Severity Gradings, Corneal Scatter, or Higher-Order Aberrations in Fuchs Endothelial Corneal Dystrophy.Investigative ophthalmology & visual science · 2024Observational
- Therapeutic applications of CRISPR/Cas9 gene editing technology for the treatment of ocular diseases.The FEBS journal · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 1 country.
Hironori UeharaPhil and Penny Knight Campus for Accelerating Scientific Impact, University of Oregon, Eugene, OR, United States.ORCID 0000-0001-6133-4918
Xiaohui ZhangPhil and Penny Knight Campus for Accelerating Scientific Impact, University of Oregon, Eugene, OR, United States.
Felipe PereiraDepartment of Ophthalmology, University of Virginia, Charlottesville, United States.
Siddharth NarendranDepartment of Ophthalmology, University of Virginia, Charlottesville, United States.
Susie ChoiMoran Eye Center, Department of Ophthalmology and Visual Sciences, University of Utah, Salt Lake City, United States.
Sai BhuvanagiriMoran Eye Center, Department of Ophthalmology and Visual Sciences, University of Utah, Salt Lake City, United States.
Jinlu LiuMoran Eye Center, Department of Ophthalmology and Visual Sciences, University of Utah, Salt Lake City, United States.
Sangeetha Ravi KumarPhil and Penny Knight Campus for Accelerating Scientific Impact, University of Oregon, Eugene, OR, United States.
Austin BohnerMoran Eye Center, Department of Ophthalmology and Visual Sciences, University of Utah, Salt Lake City, United States.
Lara CarrollMoran Eye Center, Department of Ophthalmology and Visual Sciences, University of Utah, Salt Lake City, United States.
Bonnie ArcherPhil and Penny Knight Campus for Accelerating Scientific Impact, University of Oregon, Eugene, OR, United States.
Yue ZhangDivision of Epidemiology, Department of Internal Medicine, University of Utah, Salt Lake City, United States.
Wei LiuDivision of Epidemiology, Department of Internal Medicine, University of Utah, Salt Lake City, United States.
Guangping GaoGene Therapy Center, Department of Microbiology and Physiological Science Systems, University of Massachusetts Medical School, Worcester, United States.
Jayakrishna AmbatiDepartment of Ophthalmology, University of Virginia, Charlottesville, United States.
Albert S JunWilmer Eye Institute, Johns Hopkins University, Baltimore, United States.
Balamurali K AmbatiPhil and Penny Knight Campus for Accelerating Scientific Impact, University of Oregon, Eugene, OR, United States.
University of Utah · USUniversity of Oregon · USUniversity of Virginia · USJohns Hopkins University · USUniversity of Massachusetts Chan Medical School · US
Funding
The Role of Soluble Flt-1 and Raver2 in Ocular Vascular DemarcationsR01EY017950 · NEI · UNIVERSITY OF UTAH · PI AMBATI, BALAMURALI K · 2008 to 2021
$5.2MNEI NIH HHS R01 EY017950
Abstract
A missense mutation of collagen type VIII alpha 2 chain (
Indexed as
Fuchs' Endothelial DystrophyAnimalsCodon, InitiatorCollagen Type VIIICRISPR-Cas SystemsDisease Models, AnimalGene EditingMaleMiceMice, Inbred C57BLRNA, Guide, CRISPR-Cas SystemsCodon, InitiatorCol8a2 protein, mouseCollagen Type VIIIRNA, Guide, CRISPR-Cas SystemsAdenovirusCRISPR/Cas9Fuchs endothelial corneal dystrophygeneticsgenomicshumanmouseoff-target analysis of CRISPR/Cas9
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.